$4.28
0.23% yesterday
Nasdaq, Nov 06, 10:00 pm CET
ISIN
US00773U1088
Symbol
ADVM

Adverum Biotechnologies Inc Stock price

$4.28
-1.02 19.25% 1M
+1.05 32.51% 6M
-0.39 8.35% YTD
-3.66 46.10% 1Y
-3.47 44.80% 3Y
-115.92 96.44% 5Y
-88.92 95.41% 10Y
-275.62 98.47% 20Y
Nasdaq, Closing price Thu, Nov 06 2025
-0.01 0.23%
ISIN
US00773U1088
Symbol
ADVM
Industry

Key metrics

Basic
Market capitalization
$89.8m
Enterprise Value
$45.4m
Net debt
positive
Cash
$44.4m
Shares outstanding
21.0m
Valuation (TTM | estimate)
P/E
- | negative
P/S
- | 7.0
EV/Sales
- | 3.5
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
39.3%
Return on Equity
-185.2%
ROCE
-
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
- | $12.9m
EBITDA
- | $-205.0m
EBIT
- | $-188.6m
Net Income
- | $-125.5m
Free Cash Flow
$-131.5m
Growth (TTM | estimate)
Revenue
- | 1,191.1%
EBITDA
- | -51.3%
EBIT
- | -35.5%
Net Income
- | 4.1%
Free Cash Flow
-47.6%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -1,588.0%
EBIT
-
Net
- | -972.4%
Free Cash Flow
-
More
EPS
-
FCF per Share
$-6.3
Short interest
4.8%
Employees
155
Rev per Employee
$10.0k
Show more

Is Adverum Biotechnologies Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,024 stocks worldwide.

Adverum Biotechnologies Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Adverum Biotechnologies Inc forecast:

9x Buy
75%
3x Hold
25%

Analyst Opinions

12 Analysts have issued a Adverum Biotechnologies Inc forecast:

Buy
75%
Hold
25%

Financial data from Adverum Biotechnologies Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
1 1
72% 72%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 61 61
22% 22%
6,076%
- Research and Development Expense 77 77
1% 1%
7,704%
-133 -133
13% 13%
-13,315%
- Depreciation and Amortization 3.65 3.65
35% 35%
365%
EBIT (Operating Income) EBIT -137 -137
11% 11%
-13,680%
Net Profit -129 -129
10% 10%
-12,857%

In millions USD.

Don't miss a Thing! We will send you all news about Adverum Biotechnologies Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Adverum Biotechnologies Inc Stock News

Neutral
Business Wire
11 days ago
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Adverum Biotechnologies, Inc. (NASDAQ: ADVM) to Eli Lilly and Company is fair to Adverum shareholders. Under the terms of the proposed transaction, Adverum shareholders will receive $3.56 per share in cash plus one non-transferrable contingent value right (CVR) entitling the holder to ...
Neutral
Business Wire
13 days ago
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Adverum Biotechnologies, Inc. (NasdaqCM: ADVM) to Eli Lilly and Company (NYSE: LLY). Under the terms of the proposed transaction, shareholders of Adverum will receive $3.56 per share in cash plus one no...
Neutral
PRNewsWire
14 days ago
MILWAUKEE , Oct. 24, 2025 /PRNewswire/ -- The Ademi Firm is investigating Adverum (Nasdaq: ADVM) for possible breaches of fiduciary duty and other violations of law in its transaction with Eli Lilly. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995.
More Adverum Biotechnologies Inc News

Company Profile

Adverum Biotechnologies, Inc. is a clinical-stage biotechnology company that engages in the development of novel gene therapies to treat patients with sight-threatening ophthalmic diseases. It focuses on treatment of wet age-related macular degeneration, alpha-1 antitrypsin deficiency, hereditary angioedema, friedreich's ataxia, severe allergy, color vision deficiency, and juvenile x-linked retinoschisis. The company was founded by Mark S. Blumenkranz, Thomas W. Chalberg, Jr., Mitchell H. Finer and Steven Daniel Schwartz on July 17, 2006 and is headquartered in Menlo Park, CA.

Head office United States
CEO Laurent Fischer
Employees 155
Founded 2006
Website adverum.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today